Alla studier
RekryteringTerapeutisk utforskande (Fas II)Interventionell

lmlifidase treatment tor acute inflammation in AQP4-lgG associated neuromyelitis optica spectrum disorder (DEFEAT NMOSD)

Neuromyelitis optica spectrum disorder (NMOSD), sometimes called Devic's disease, is a rare condition where the immune system mistakenly attacks the nerves in the eyes and spinal cord. During a sudden attack or flare-up, harmful proteins called anti-AQP4 antibodies cause severe swelling and damage. This Phase II clinical trial is testing a medicine called Idefirix (imlifidase). Idefirix is an enzyme given through a drip that rapidly breaks down these damaging antibodies. The main goal of the study is to find out if Idefirix can completely clear these harmful antibodies from the bloodstream within six hours of treatment. Adults aged 18 and older who have NMOSD and are having an active attack may be able to take part. Researchers hope this quick-acting treatment could offer a better way to protect sight and movement during serious attacks.

Överblick

Status
Rekrytering
Fas
Terapeutisk utforskande (Fas II)
Sponsor
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Inskrivningsmål
5
Starta
10 Sep 2024

Vad handlar denna studie om?

Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic's disease, is a rare autoimmune condition. In healthy bodies, the immune system makes antibodies to fight off germs. In NMOSD, the body makes rogue antibodies called anti-AQP4 that mistakenly attack healthy cells, mainly in the optic nerves that connect the eyes to the brain, and in the spinal cord.

When NMOSD flares up, it can cause sudden, painful swelling. This can lead to serious problems like sight loss, weakness, numbness, and trouble walking. Current emergency treatments do not always remove the harmful antibodies quickly enough to stop permanent nerve injury.

This trial is testing a medicine called Idefirix (imlifidase). Idefirix works like a pair of microscopic scissors, cutting up and destroying IgG antibodies in the blood within hours. Doctors want to see if giving Idefirix through a vein can clear the damaging anti-AQP4 antibodies below detectable levels inside six hours.

If the study is successful, it could provide doctors with a powerful emergency rescue tool to halt nerve damage during attacks. This could help preserve eyesight and mobility for people living with this challenging condition.

Viktiga punkter

  • The trial tests Idefirix to see if it quickly removes harmful antibodies during an NMOSD attack.
  • Researchers are measuring whether antibody levels drop significantly within six hours.
  • The study is for adults aged 18 and over who have tested positive for anti-AQP4 antibodies.
  • The medicine is given as a single drip in a hospital setting with close monitoring.
  • Taking part is voluntary, and you can withdraw from the study at any point.

Vem kan vara berättigad?

This trial is open to adults aged 18 and over who have been diagnosed with neuromyelitis optica spectrum disorder (NMOSD) or Devic's disease.

To be considered, participants must have tested positive for the specific antibody linked to the condition (anti-AQP4 antibodies) and be experiencing an active, acute flare-up of symptoms that requires urgent treatment.

People who have serious active infections, specific allergies to the study medicine, or other severe health conditions that make taking part unsafe may not be able to join. The study team will review your full medical history before you can take part.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. You are aged 18 or older.
  2. You have a confirmed diagnosis of NMOSD or Devic's disease.
  3. You have tested positive for anti-AQP4 antibodies.
  4. You are currently experiencing an acute attack or sudden flare-up of symptoms.
  5. You are able to attend hospital for treatment and follow-up checks.
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you take part, you will receive the study medicine, Idefirix, as a single infusion through a drip into a vein. This takes place in a hospital clinic under close medical supervision.

You will have regular blood tests, including tests taken before the drip and within six hours after receiving it, to check how quickly the harmful antibodies disappear. The doctors will also check your vision, nerve function, and general well-being.

After the infusion, you will have follow-up visits and health checks over several weeks or months so the team can monitor your recovery, watch for any side effects, and make sure your immune system stays safe.

Potentiella risker och fördelar

Taking part may help clear harmful antibodies quickly during an attack, which could potentially limit nerve injury, though this cannot be guaranteed. The study will also help researchers find better future treatments for NMOSD. However, there are risks. Because Idefirix temporarily clears protective antibodies as well as harmful ones, you may have a higher risk of catching infections for a few weeks. There is also a risk of allergic reactions to the drip. Joining is completely voluntary, and you can withdraw at any time without your normal NHS care being affected.

Platser (1)

Vissa platsangivelser är ungefärliga. Vi arbetar på att förbättra detta — vänligen kontrollera med testteamet innan du reser.
  • —
    Obekräftad
    Nederländerna

Vanliga frågor

What is Idefirix?

Idefirix is a medicine made from an enzyme that quickly breaks down and clears certain antibodies from your bloodstream.

Is this a permanent cure for NMOSD?

No, it is not a cure. It is designed as a rapid emergency treatment to stop antibody damage during an acute flare-up.

Hur ges studiemedicinen?

It is given directly into a vein through a drip (infusion) in hospital while doctors and nurses monitor you closely.

Will I still receive standard emergency care?

The study doctors will ensure your safety is the top priority and will discuss how this trial fits alongside standard hospital care.

Can I leave the trial if I change my mind?

Yes, you can leave the study at any time. Your decision will not change the standard of medical care you receive from your doctors.

Hur du får reda på mer

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "lmlifidase treatment tor acute inflammation in AQP4-lgG asso…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.